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Available online 13 April 2016The human embryonic stem cell line RCe018-A (RC-14) was derived under quality assured compliance with UK
regulation, EuropeanUnionDirectives and International guidance for tissue procurement, processing and storage
according toGoodManufacturing Practice (GMP) standards. The cell linewas derived from a blastocyst stage em-
bryo voluntarily donated as unsuitable or surplus to fertility requirements following informed consent. RCe018-A
(RC-14) showsnormal pluripotencymarker expression and differentiation to the three germ layers in vitro. It has
a male karyotype with an extra copy of chromosome 8 (47XY, +8). Microsatellite PCR identity, HLA and blood
group typing data are available.
© 2016 Roslin Cells Ltd. Published by Elsevier B.V. This is an open access article under the CC BY license
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RCe018-A (RC-14)wasderived fromablastocyst stage embryo thatwas
surplus to requirement or unsuitable for clinical use. Human embryonic
stem cell (hESC) isolation, expansion and qualiﬁcation were performed
in facilities whose speciﬁcation, operation and monitoring complied with
GMP standards enabling; i) a fully traceable procurement procedure
with informed ethical consent which includes provision for commercial
use, ii) detailed medical history and blood borne virus (BBV) screening of
donors, and iii) compilation of a cell line history providing details on hESC
manufacturing process and quality control testing regime.
Human ESC culture and processing was performed in a grade A tissue
culture cabinet in a grade B clean room environment monitored for par-
ticulate and microbiological contamination during cell processing in ac-
cordance with Rules and Guidance for Pharmaceutical Manufacturers
and Distributors — The Orange Guide, compiled by the UK Medicines
Healthcare Products Regulatory Authority (go to: https://www.gov.uk/mmons.org/licenses/by/4.0/).
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Accordingly, the facility was operating under a mature Quality Manage-
ment System, compliant with ISO9001:2008 standards. hESC derivation
was performed under licensure from the UK HFEA (R0136 to centre
0202) and HTA (Licensing Number 22631).
hESC derivation involved whole embryo outgrowth on mitotically
inactivated humandermalﬁbroblast (HDF) feeder cells. HDFswere derived
andmanufacturedaccording toGMPandhadbeenapproved for clinical use
by the Food and Drug Administration, USA. During derivation on HDFs,
hESCs were grown in a xeno-free cell therapy grade media (XF KODMEM)
supplemented with xeno-free human recombinant bFGF. hESCs were
subsequently expanded in a GMP grade serum-free medium (StemPro
hESC Serum Free Medium) on a xeno-free matrix (CellStart). The former
contained bovine serum albumin (BSA) from a Transmissible Spongiform
Encephalopathy (TSE)-free country of origin. The cell line was cryopre-
served in a GMP compliant cryopreservation solution (CryoStor CS10).
By ﬂow cytometry, RCe018-A (RC-14) expressed the pluripotency
makersOct-4, Tra-1-60 and SSEA-4 (87.7%, 55.4% and94.8%, respectively),
whereas low expression of the differentiation marker SSEA-1 (1.0%) was
observed (Figs. 1 and 2). Differentiation to the three germ layers,Fig. 1. Quality Control Certiﬁcate of Analysiendoderm, ectoderm and mesoderm, was demonstrated using embryoid
body formation in vitro, and expression of the germ layer markers α-
fetoprotein, β-tubulin and muscle actin was observed (Fig. 3).
A microsatellite PCR proﬁle has been obtained for the cell line, and
HLA Class I and II typing is available (Table 1). Blood group genotyping
gave the blood group O1O1 (Table 1).
Veriﬁcation and authentication
The cell line was analysed for genome stability by G-banding and
showed amale genotypewith trisomy 8 (47XY,+8) in all cells analysed
(Fig. 4). The cell line is free from mycoplasma contamination as deter-
mined by RT-qPCR.
Materials and methods
Ethics
Derivation of hESC from surplus to requirement and failed to
fertilise/develop embryos was approved by The Scotland A Researchs for RCe018-A (RC-14) P28A seed lot.
Fig. 1 (continued).
Fig. 2. RCe018-A (RC-14) was subjected to ﬂow cytometry analysis for markers of pluripotency with speciﬁc antibody (top row) or isotype control (bottom row) as indicated above the
histograms. Percentage staining is indicated in the Certiﬁcate of Analysis (Fig. 1).
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Fig. 3. In vitro differentiation of RCe018-A (RC-14) to ectoderm (β-tubulin III), mesoderm (muscle Actin), and endoderm (α-fetoprotein). Speciﬁc staining shown in green, cell nuclei are
counterstained with DAPI (blue).
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and conducted under licence no R0136 from the UK HFEA with in-
formed donor consent. The processing and storage of hESC for human
application were conducted under licence number 22631 from the UK
Human Tissue Authority.Cell culture
Fresh embryoswere cultured in Sydneyblastocystmedium(CookMed-
ical, Hertfordshire, UK) after day 3 of development. Embryoswere cultured
at 36.5–37.5 °C, 5.0 ± 0.5% CO2, 5.0 ± 0.5% O2 in drops under parafﬁn oil
(Cook Medical) and transferred to fresh medium at least every 2–3 days.
By day 8 of development, embryos were placed in derivation condi-
tions consisting of mitotically inactivated GMP grade neonatal human
dermal ﬁbroblasts (HDFs) (Forticell Biosciences, NJ, USA) on tissue cul-
ture plastic in XF KODMEM medium (Knockout-DMEM, 15% KOSR-XF,
2 mM L-glutamine, 1% MEM nonessential amino acids, 2% XF Growth
Factor Cocktail, 0.1 mM β-mercaptoethanol (ThermoFisher Scientiﬁc,
Paisley, UK) supplemented with 80 ng/ml human bFGF (ThermoFisher
Scientiﬁc). When available, cell therapy system quality reagents were
used. Assisted hatchingwas performed by removing the zonapellucidae
mechanically using Swemed cutting tools (Vitrolife, Göteborg, Sweden).
HDF cells were cultured in DMEM (Lonza, Slough, UK), 10% Pharma
grade FCS (GE Healthcare (PAA), Buckinghamshire, UK) and 2 mM L-
glutamine (ThermoFisher Scientiﬁc). HDF were mitotically inactivated
using gamma irradiation at 50 Gy using a Gammacell Elite 1000 ma-
chine. For use as a feeder layer, irradiated HDFs were plated at
50,000 cells/cm2 in XF KODMEM medium supplemented withTable 1
Microsatellite PCR, blood group and HLA tissue typing results for RCe018-A (RC-14).
Microsatellite PCR results
D3S1358 1 D3S1358 2 vWA 1 vWA 2
16 16 16 16
Amelogenin 1 Amelogenin 2 D8S1179 1 D8S1179 2
X Y 12 12
D19S433 1 D19S433 2 THO1 1 THO1 2
13 16 9.3 9.3
D5S818 1 D5S818 2 D7S820 1 D7S820 2
9 11 8.2 12
Blood group genotyping
RhD RhC Rhc RhE
pos pos neg neg
Jka Jkb K k
pos neg neg pos
Do a Do b ABO
neg pos O1O1
HLA tissue typing
HLA Class I Type
HLA Class II Type
Comment
*Peak falls below threshold to conﬁdently score.80 ng/ml human bFGF (ThermoFisher Scientiﬁc). Cells were cultured
at 36.5–37.5 °C, 5.0 ± 0.5% CO2, 5.0 ± 0.5% O2 and 50% medium ex-
changed 6 days a week.
The established cell linewas expandedandbankedusingCellStartma-
trix and Stempro hESC Serum Free Medium (cell therapy system quality
reagents, ThermoFisher Scientiﬁc). This contained BSA from a TSE-free
country of origin. Passagingwas performedmechanically using an EZ pas-
sage tool (ThermoFisher Scientiﬁc). hESC lines were expanded to 25–30
wells of a 6-well plate and cryopreserved in 0.5–1 ml CryoStor CS10
(Biolife Solution, Washington, USA) using an EF600-107 controlled rate
freezer (Grant Instruments, Cambridge, UK) before being stored in a
−150 °C freezer (Panasonic Biomedical, Loughborough, UK).
Mycoplasma
In process mycoplasma detection was performed using Applied
Biosystems PrepSEQ™ Mycoplasma Nucleic Acid Extraction Kit and
MicroSEQ™MycoplasmaReal-TimePCRDetectionKit (ThermoFisher Sci-
entiﬁc (Applied Biosystems)) according to themanufacturer's instruction.
Endotoxin
Endotoxin levels were determined using the Kinetic-QCL assay
(Lonza) and an incubating plate reader (BioTek ELx808) according to
the manufacturer's instructions. Brieﬂy, an unknown sample was com-
pared with a standard curve of known levels of control endotoxin. An
assay was deemed valid if the coefﬁcient of correlation, r ≥ 0.980 and
the CV (%) for the standard curve was ≤10%, and the reaction time ofD16S539 1 D16S539 2 D2S1338 1 D2S1338 2
10 12 17 24
D21S11 1 D21S11 2 D18S51 1 D18S51 2
30 31.2 16 16
FGA 1 FGA 2 CSF1PO 1 CSF1PO 2
20 24 10 10
D13S317 1 D13S317 2 TPOX 1 TPOX 2
11 14 8 12
Rhe Fy a Fy b Fy GATA
pos pos neg neg
M N S s
pos pos neg pos
HLA-A*01, A*02; B*07, B*08; C*07
HLA-DRB1*03; DRB3*01/02; DQB1*02
DRB1*03 is expressed serologically as DR17.
Fig. 4. RCe018-A (RC-14) was analysed by Giemsa staining of 30 metaphase spreads and showed a 47XY, +8 male karyotype in all spreads analysed.
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standard on the standard curve.
Flow cytometry
Pluripotency was determined using the Human and Mouse Pluripo-
tent Stem Cell Analysis kit (BD, Oxford, UK). Oct 3/4 and SSEA-4 were in-
cluded as pluripotency markers, and SSEA-1 as a differentiation marker.
FITC conjugated Tra-1-60 (BD) was used as an additional pluripotency
marker. Fixed and permeabilised cells were analysed using a FACS Aria
ﬂowcytometer (BD) or aGuava easyCyteﬂowcytometer (Millipore,Wat-
ford, UK). Percentage expression of eachmarkerwas compared to isotype
control or unstained cells.
Viability
Viability was determined using the Guava ViaCount assay. Brieﬂy, the
Guava ViaCount reagent (Millipore) containing a nuclear and a viability
dye, was mixed with a single cell suspension, incubated for 5 min and
analysed using the Guava easyCyte ﬂow cytometer (Millipore). Total
cell count, viable cell count and percentage viable cells were obtained.
In vitro differentiation
hESCs were pre-treated for 1 h with 10 μM ROCK inhibitor in
Stempro hESC SFM (ThermoFisher Scientiﬁc) and embryoid bodies
(EBs) generated in ultra low attachment plates (Corning) for 7 days be-
fore being transferred into EBmedium (20% FBS (GE Healthcare (PAA)),
80% KO-DMEM 1 mM L-glutamine, 3.5 μM β-mercaptoethanol, 1% non-
essential amino acids (all ThermoFisher Scientiﬁc)), on glass slide tissue
culture chambers (Nunc, ThermoFisher Scientiﬁc) coated with 0.2% gel-
atin (Sigma Aldrich, Dorset, UK) at 0.1 ml/cm2 for 14 days.
Immunocytochemistry
Cells were ﬁxed in 4% paraformaldehyde (ThermoFisher Scientiﬁc
(Alfa Aesar)), permeabilised using 100% ethanol (ThermoFisherScientiﬁc) and stained with AFP (1:500; Sigma), β-tubulin III (1:1000;
Sigma) and muscle-speciﬁc actin (1:50; DAKO, Glostrup, Denmark)
and secondary antibody anti mouse IgG-AlexaFluor 488 (1:200;
Sigma). Images were acquired using a Zeiss S100 Axiovert ﬂuorescence
microscope or Nikon eC1 confocal microscope.
Genomic analysis and outsourced assays
All outsourced assays were carried out under a Quality and Tech-
nical Agreement. DNA was extracted using the QIAamp DNAMini kit
(Qiagen, Manchester, UK) according to manufacturer's recommen-
dations and provided in recommended quantities to the service
providers.
Microsatellite PCR, or Short Tandem Repeat analysis, was used to
determine cell line identity and was carried out by Public Health
England. A proﬁle was obtained for the following core alleles: vWA,
D16S539, Amelogenin, THO1, CSF1PO, D5S818, D75820, D135317 and
TPOX.
Human Leukocyte Antigen (HLA) tissue typing was carried out by
the Scottish National Blood Transfusion Service.
Blood group genotyping was carried out by the Molecular Diagnos-
tics laboratory at NHSBT.
Karyotype analysis was carried out by the Western General Cytoge-
netics Laboratory (Edinburgh, UK). Live cells at 60–70% conﬂuencywere
shipped in warm containers, ﬁxed and analysed by standard G-banding
analysis. For clinical grade lines, 30 spreads were analysed.
Viral screening for cytomegalovirus (CMV), Human T-cell
lymphotropic virus (HTLV)-1, Human immunodeﬁciency virus
(HIV)-1, Hepatitis C virus (HCV), Hepatitis B virus (HBV) and
Epstein–Barr virus (EBV) was carried out by The Doctors Laboratory
(London, UK).
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